Roche / Genentech Clinical Trial Pipeline — 246 Active Studies

Phases, active trials: Phase 1: 53, Phase 2: 75, Phase 3: 89, Other: 29

Roche and its US subsidiary Genentech operate one of the deepest oncology and immunology pipelines in the industry. Their PD-L1 checkpoint inhibitor Tecentriq (atezolizumab) anchors a broad combination program across solid tumors. In hematology, obinutuzumab, polatuzumab vedotin, and CD20xCD3 bispecific antibodies (mosunetuzumab, glofitamab) represent a comprehensive B-cell malignancy platform. In neuroscience, Ocrevus (ocrelizumab) for multiple sclerosis and the Alzheimer's pipeline (gantenerumab follow-ons) drive significant clinical activity. Roche's bispecific antibody platform is among the industry's most prolific — generating multiple new trials annually.

• Oncology (hematology, solid tumors)
• Neuroscience (MS, Alzheimer's)
• Immunology / ophthalmology
• Bispecific antibodies
• Blood cancers / lymphoma

• Tecentriq (atezolizumab) — PD-L1 checkpoint inhibitor
• Ocrevus (ocrelizumab) — multiple sclerosis
• Polivy (polatuzumab vedotin) — DLBCL ADC
• Lunsumio (mosunetuzumab) — CD20xCD3 bispecific
• Columvi (glofitamab) — CD20xCD3 bispecific
• Faricimab — bispecific ophthalmology (AMD, DME)

Roche consistently generates the highest volume of new bispecific antibody trial registrations in hematology. Their oncology-neuroscience breadth means new trials span many indication categories — a Roche watchlist captures programs across lymphoma, MS, and ophthalmology simultaneously.

DataLookout monitors ClinicalTrials.gov daily and surfaces changes to Roche / Genentech's registered studies: new trial registrations, status transitions (for example "Not yet recruiting" to "Recruiting"), site additions, and protocol amendments. This is the intelligence layer that bridges the gap between quarterly investor calls and day-to-day pipeline developments.

• Sponsor normalization: Roche / Genentech may register trials under multiple legal entity names. DataLookout normalizes all related entities to a single canonical sponsor for complete pipeline coverage.
• Daily updates: ClinicalTrials.gov is queried each morning. New registrations and updates appear in that day's digest.
• Field-level change detection: Status changes, enrollment updates, and site additions are detected and surfaced, not just new registrations.
• Phase filtering: Focus on Phase 3 pivotal trials, Phase 2 proof-of-concept studies, or all phases for comprehensive coverage.
• Indication filtering: Combine sponsor monitoring with indication keywords to focus on the therapeutic areas relevant to your business.